| Title |
Muscle relaxants for pain management in rheumatoid arthritis
|
|---|---|
| Published in |
Cochrane database of systematic reviews, January 2012
|
| DOI | 10.1002/14651858.cd008922.pub2 |
| Pubmed ID | |
| Authors |
Bethan L Richards, Samuel L Whittle, Rachelle Buchbinder |
| Abstract |
Pain management is a high priority for patients with rheumatoid arthritis (RA). Muscle relaxants include drugs that reduce muscle spasm (for example benzodiazepines such as diazepam (Valium), alprazolam (Xanax), lorazepam (Ativan) and non-benzodiazepines such as metaxalone (Skelaxin) or a combination of paracetamol and orphenadrine (Muscol)) and drugs that prevent increased muscle tone (baclofen and dantrolene). Despite a paucity of evidence supporting their use, antispasmodic and antispasticity muscle relaxants have gained widespread clinical acceptance as adjuvants in the management of patients with chronic musculoskeletal pain. |
X Demographics
The data shown below were collected from the profiles of 31 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 8 | 26% |
| United Kingdom | 3 | 10% |
| Spain | 2 | 6% |
| Australia | 2 | 6% |
| Colombia | 2 | 6% |
| France | 2 | 6% |
| India | 1 | 3% |
| Ireland | 1 | 3% |
| Italy | 1 | 3% |
| Other | 1 | 3% |
| Unknown | 8 | 26% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 29 | 94% |
| Practitioners (doctors, other healthcare professionals) | 1 | 3% |
| Science communicators (journalists, bloggers, editors) | 1 | 3% |
Mendeley readers
The data shown below were compiled from readership statistics for 312 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Colombia | 1 | <1% |
| United Kingdom | 1 | <1% |
| Peru | 1 | <1% |
| Sri Lanka | 1 | <1% |
| Spain | 1 | <1% |
| United States | 1 | <1% |
| Unknown | 306 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 43 | 14% |
| Student > Ph. D. Student | 34 | 11% |
| Student > Bachelor | 31 | 10% |
| Researcher | 28 | 9% |
| Student > Doctoral Student | 24 | 8% |
| Other | 60 | 19% |
| Unknown | 92 | 29% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 95 | 30% |
| Nursing and Health Professions | 27 | 9% |
| Psychology | 22 | 7% |
| Pharmacology, Toxicology and Pharmaceutical Science | 17 | 5% |
| Neuroscience | 7 | 2% |
| Other | 36 | 12% |
| Unknown | 108 | 35% |
Attention Score in Context
This research output has an Altmetric Attention Score of 32. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 February 2024.
All research outputs
#1,256,660
of 25,806,763 outputs
Outputs from Cochrane database of systematic reviews
#2,609
of 13,140 outputs
Outputs of similar age
#7,938
of 253,476 outputs
Outputs of similar age from Cochrane database of systematic reviews
#29
of 235 outputs
Altmetric has tracked 25,806,763 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 13,140 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 35.9. This one has done well, scoring higher than 80% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 253,476 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 96% of its contemporaries.
We're also able to compare this research output to 235 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 87% of its contemporaries.